Cargando…
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance
Sorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are modest, and as its mechanisms of action remain elusive, a better understanding of its anticancer effects is needed. Based on our previous study...
Autores principales: | Emma, M R, Iovanna, J L, Bachvarov, D, Puleio, R, Loria, G R, Augello, G, Candido, S, Libra, M, Gulino, A, Cancila, V, McCubrey, J A, Montalto, G, Cervello, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143401/ https://www.ncbi.nlm.nih.gov/pubmed/27336713 http://dx.doi.org/10.1038/cddis.2016.175 |
Ejemplares similares
-
Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells
por: Cervello, Melchiorre, et al.
Publicado: (2013) -
Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
por: Cusimano, Antonella, et al.
Publicado: (2014) -
The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
por: Augello, Giuseppa, et al.
Publicado: (2020) -
New landscapes and horizons in hepatocellular carcinoma therapy
por: Cervello, Melchiorre, et al.
Publicado: (2020) -
Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity
por: Chappell, William H., et al.
Publicado: (2012)